Humacyte, Inc. (NASDAQ:HUMA) Given Average Recommendation of “Buy” by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been given an average rating of “Buy” by the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $13.71.

A number of research analysts have commented on HUMA shares. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research note on Tuesday, January 21st. TD Cowen restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. BTIG Research reiterated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Benchmark upped their target price on shares of Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, December 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target (up from $12.00) on shares of Humacyte in a report on Friday, December 20th.

Humacyte Price Performance

NASDAQ HUMA opened at $4.01 on Friday. The company’s fifty day moving average is $4.51 and its two-hundred day moving average is $5.35. The firm has a market capitalization of $504.70 million, a price-to-earnings ratio of -2.99 and a beta of 1.30. Humacyte has a 52-week low of $2.81 and a 52-week high of $9.97.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the sale, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the sale, the chief executive officer now owns 2,419,712 shares of the company’s stock, valued at approximately $10,743,521.28. This represents a 25.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,500,000 shares of company stock valued at $6,606,799. 11.20% of the stock is owned by corporate insiders.

Institutional Trading of Humacyte

Several institutional investors have recently added to or reduced their stakes in HUMA. Vanguard Group Inc. boosted its position in shares of Humacyte by 10.8% in the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after acquiring an additional 543,995 shares during the period. State Street Corp boosted its holdings in Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after purchasing an additional 1,895,529 shares during the period. Geode Capital Management LLC boosted its holdings in Humacyte by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock valued at $11,101,000 after purchasing an additional 179,120 shares during the period. Millennium Management LLC boosted its holdings in Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after purchasing an additional 1,334,641 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Humacyte by 7.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 775,718 shares of the company’s stock valued at $3,917,000 after purchasing an additional 54,400 shares during the period. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.